|
|
Ultrasonic Detection, Propulsion + Comminution of Kidney Stones
Current Research at the University of Washington
|
Research, Development, Commercialization
|
|
FDA Clearance
|
We report results from several clinical trials of our investigational device that is an alternative to surgery for fragmenting and facilitating clearance of small, asymptomatic renal stones. Our office-based unltrasound system images, breaks, and repositions stone fragments to facilitate their natural clearance in the urine.
Our University-based research has progressed through theoretical and laboratory studies, work in animal models, human feasibility studies, and randomized human clinical trials with results submitted to FDA. We continue to improve the technologies.
We have now compiled a data base of over 200 study participants who have undergone a procedure with these investigational technologies without serious adverse events.
|
|
|
SonoMotion announces FDA clearance for its Break Wave lithotripsy device for treatment of kidney stones
21 January 2026
PR Newswire
SonoMotion announced that it received FDA 510(k) clearance for its Break Wave lithotripsy device. The technology licensed from UW and commercialized by SonoMotion non-invasively fragments stones in the kidney or ureter on fully awake patients, without anesthesia, and at any site of care. |
|
 |
|
SonoMotion announces FDA de novo clearance for its Stone Clear device
13 November 2024
PR Newswire
SonoMotion's Stone Clear is the first and only FDA-cleared device using non-invasive ultrasound pulses to facilitate passage of kidney stone fragments post-lithotripsy without surgery and in any health care setting. |
|
 |
|
|
Ultrasonic Propulsion Clears Residual Stone Fragments
|
|
|
|
|
|
A study conducted at the University of Washington and the VA of Puget Sound demonstrates that ultrasonic propulsion of residual kidney stone fragments reduces relapse for patients who have undergone stone intervention treatments.
The investigational team reports results of a trial conducted with 82 people from 2015 to 2024. Repositioning residual fragments in the treatment group results in a 70% lower incidence of relapse urgent medical visit or a subsequent surgery. Time to relapse was also longer by nearly 1.5 years in the treatment group.
"This study is the culmination of our work to invent ultrasonic propulsion to remove kidney stone fragments. Our treatment technology and clinical methods reduce the number of patients who return to the emergency room or their urologist with stone problems." Mike Bailey
|
|
|
 |
|
Randomized controlled trial of ultrasonic propulsion-facilitated clearance of residual kidney stone fragments vs. observation Sorensen, M.D., and 16 others including B. Dunmire, J. Thiel, B.W. Cunitz, J.C. Kucewicz, and M.R. Bailey, "Randomized controlled trial of ultrasonic propulsion-facilitated clearance of residual kidney stone fragments vs. observation," J. Urol., 212, 811-820, doi:10.1097/JU.0000000000004186, 2024. |
|
More Info
| |
|
1 Dec 2024
|
|
 |
|
|
Ultrasonic propulsion is an investigational procedure for awake patients. Our purpose was to evaluate whether ultrasonic propulsion to facilitate residual kidney stone fragment clearance reduced relapse.
This multicenter, prospective, open-label, randomized, controlled trial used single block randomization (1:1) without masking. Adults with residual fragments (individually 5 mm or smaller) were enrolled. Primary outcome was relapse as measured by stone growth, a stone-related urgent medical visit, or surgery by 5 years or study end. Secondary outcomes were fragment passage within 3 weeks and adverse events within 90 days. Cumulative incidence of relapse was estimated using the Kaplan-Meier method. Log-rank test was used to compare the treatment (ultrasonic propulsion) and control (observation) groups.
The trial was conducted from May 9, 2015, through April 6, 2024. Median follow-up (interquartile range) was 3.0 (1.83.2) years. The treatment group (n = 40) had longer time to relapse than the control group (n = 42; P < .003). The restricted mean time-to-relapse was 52% longer in the treatment group than in the control group (1530 ± 92 days vs 1009 ± 118 days), and the risk of relapse was lower (hazard ratio 0.30, 95% CI 0.130.68) with 8 of 40 and 21 of 42 participants, respectively, experiencing relapse. Omitting 3 participants not asked about passage, 24 treatment (63%) and 2 control (5%) participants passed fragments within 3 weeks of treatment. Adverse events were mild, transient, and self-resolving, and were reported in 25 treated participants (63%) and 17 controls (40%).
|
|
|
|
Human Study Combines BWL and UP Treatment
|
|
|
|
|
|
The Laboratory and University research team demonstrates that burst wave lithotripsy (BWL) followed by ultrasonic propulsion (UP) in a clinical setting clears over 70% of asymtomatic, small renal stones in awake patients. This is the first human feasibility study that uses both technologies together to clear stones.
As in preceding trials, all participants tolerated the procedure without anesthesia or medication.
Based on this successful study, the team anticipates a larger efficacy trial.
|
|
|
 |
|
Facilitated clearance of small, asymptomatic renal stones with burst wave lithotripsy and ultrasonic propulsion Harper, J.D., and 18 others including B. Dunmire, J. Thiel, Y.-N. Wang, S. Totten, J.C. Kucewicz, and M.R. Bailey, "Facilitated clearance of small, asymptomatic renal stones with burst wave lithotripsy and ultrasonic propulsion," J. Urol., 214, 41-47, doi:10.1097/JU.0000000000004533, 2025. |
|
More Info
| |
|
1 Jul 2025
|
|
 |
|
|
We tested feasibility of burst wave lithotripsy (BWL) and ultrasonic propulsion to noninvasively fragment and expel small, asymptomatic renal stones in awake participants.
Adult patients suspected of having 2- to 7-mm stones were consented and screened for eligibility. BWL and ultrasonic propulsion were applied to up to 3 stones in 1 kidney of qualifying participants for a 30-minute total exposure. Participants completed a CT scan and the Wisconsin Stone Quality-of-Life (WISQOL) questionnaire within 90 days before and 120 days after the procedure. Participants were contacted weekly for 3 weeks after the procedure to assess adverse events (AEs). Outcomes included (1) no fragment > 2 mm, (2) unanticipated health care visits, (3) change in stone volume, (4) reported AEs, and (5) WISQOL score.
Forty-one participants were enrolled between April 2023 and October 2024. Twenty-one participants failed screening because no stones were seen, stones were too large or small, stone visibility was too deep or obstructed, or they declined to participate. Twenty participants with 31 stones received the research procedure with 7 undergoing a single repeat procedure. Twenty-two of 31 stones (71%) met the primary effectiveness outcome of no fragment > 2 mm, with 17 of 31 stones (55%) reported as stone free. Median stone volume reduction (IQR) was 100% (88%100%). No participants returned unexpectedly for care related to the procedure. AEs were all Grade I by modified Clavien classification. WISQOL scores improved on 10 of 15 completed questionnaires.
Small, asymptomatic renal stones were effectively and safely removed in awake participants in a clinic setting.
|
|
|
|
Indpendent Replication of Results
|
|
|
|
|
|
Ultrasonic Propulsion Clears Residual Renal Stone Fragments
In patients with residual stone fragments, ultrasonic propulsion (UP) increased the fragment passage rate by 58% and reduced risk of relapse by 70% vs. untreated controls with minor associated adverse events. This study presents a second, independent trial of UP to demonstrate replication of those results and effective training of a novice team of users.
None of the UP operators in this study had previous experience with UP for the clearance of renal stone fragments. With training, they obtained similar results to the original study Sorensen et al., above by a team of experienced device users.
These results contributed to FDA clearance of the first UP device.
|
|
|
|
A randomized controlled trial of ultrasonsic propulsion-facilitated clearance of residual renal stone fragments vs. observation
Yang, C.C., and 5 others, "A randomized controlled trial of ultrasonsic propulsion-facilitated clearance of residual renal stone fragments vs. observation," J. Urol, 214, 3-9, doi:10.1097/JU.0000000000004501, 2025. 3 March 2025 |
|
 |
|
|
An Investigational Ultrasound System for Kidney Stone Managment
|
|
|
|
|
|
This is the first new kidney stone management system in 30 years. It's a revolutionary treatment.
NASA funded us to invent this technology that can, with the transducer probe pressed up against the skin, use the sound wave force to push stones, and to direct their movement out of the kidney.
This new treatment is non-invasive and powered by focused ultrasound, providing safe, timely management of kidney stones on Earth and, very soon, in space.
|
|
|
|
|
Tractor Beams |
Continuing R+D |
Benefits: Urologists + Patients |
|
|
Tractor beam doesn’t sound very scientific it sounds like science fiction. But these acoustic waves can be focused and shaped to build a cage of pressure around the stone.
We’re working on a complicated system in the lab to make the acoustic beams and also getting straight to the clinic and trying this with the existing system we’ve built that can push, break, and image stones.
|
|
Treating Stone Disease in Pet Cats and Marine Mammals
|
|
|
|
|
|
Developing this system, we've worked with many urologists. One of them suggested this could be an excellent technology for veterinary applications. Now we've relieved painful, medical emergencies in pet cats and marine mammals in human care.
|
|
Videos Produced by NSBRI
|
|
|
Pushing Kidney Stones Part 1 |
Part 2 |
|
|
Astronauts have a higher risk of developing kidney stones because of the microgravity environment. They can put an astronaut out of commission or be life-threatening. We have to develop a capability that does not require surgery, a urologist, or ionizing radiation. Ultrasound fits the bill.
|
|
From Researchers' Ideas to Clinical Trials
|
|
|
Patient Trials Begin |
Pathway to Clinic |
Prototype Demo |
R & D |
|
|
This dedicated ultrasound system is capable of non-invasive, real-time, image-guided repositioning of kidney stones. We can move stones while patients are awake so there’s no pain this can be an office procedure. The real goal is to relocate small stones to facilitate their passage.
This is completely novel technology. There’s nothing like it out there.
|
|
Clinical Validation Study
|
|
|
Presentation by Mike Bailey, February 2021
|
|
|
Renal Stone Management Technology Development and Clinical Validation Study (PDF, 20 MB)
Presentation at Breaking Boundaries: Advancing Human Space Flight Research Through Innovation and Collaboration, organized by NASA, February 2021 |
|
 |
|
|
First-in-Human Feasibility Study
|
|
|
|
|
|
In almost every clinical trial patient, we could reposition stones with ultrasound. In one dramatic case, small stones were actually passed within hours of the study treatment.
|
|
Feasibility Study Results
|
 |
|
Ultrasonic propulsion of kidney stones May, P.C., M.R. Bailey, and J.D. Harper, "Ultrasonic propulsion of kidney stones," Curr. Opin. Urol., 26, 264-270, doi:10.1097/MOU.0000000000000276, 2016. |
|
More Info
| |
|
1 May 2016
|
|
 |
|
|
Ultrasonic propulsion is a novel technique that uses short bursts of focused ultrasonic pulses to reposition stones transcutaneously within the renal collecting system and ureter. The purpose of this review is to discuss the initial testing of effectiveness and safety, directions for refinement of technique and technology, and opinions on clinical application.
Preclinical studies with a range of probes, interfaces, and outputs have demonstrated feasibility and consistent safety of ultrasonic propulsion with room for increased outputs and refinement toward specific applications. Ultrasonic propulsion was used painlessly and without adverse events to reposition stones in 14 of 15 human study participants without restrictions on patient size, stone size, or stone location. The initial feasibility study showed applicability in a range of clinically relevant situations, including facilitating passage of residual fragments following ureteroscopy or shock wave lithotripsy, moving a large stone at the ureteropelvic junction with relief of pain, and differentiating large stones from a collection of small fragments.
Ultrasonic propulsion shows promise as an office-based system for transcutaneously repositioning kidney stones. Potential applications include facilitating expulsion of residual fragments following ureteroscopy or shock wave lithotripsy, repositioning stones prior to treatment, and repositioning obstructing ureteropelvic junction stones into the kidney to alleviate acute renal colic.
|
|
 |
|
First-in-human clinical trial of ultrasonic propulsion of kidney stones Harper, J.D., B.W. Cunitz, B. Dunmire, F.C. Lee, M.D. Sorensen, R.S. Hsi, J. Thiel, H. Wessells, J.E. Lingeman, and M.R. Bailey, "First-in-human clinical trial of ultrasonic propulsion of kidney stones," J. Urol., 195, 956-964, doi:10.1016/j.juro.2015.10.131, 2016. |
|
More Info
| |
|
1 Apr 2016
|
|
 |
|
|
Ultrasonic propulsion is a new technology using focused ultrasound energy applied transcutaneously to reposition kidney stones. We report the findings from the first human investigational trial of ultrasonic propulsion toward the applications of expelling small stones and dislodging large obstructing stones.
Subjects underwent ultrasonic propulsion either awake without sedation in clinic or during ureteroscopy while anesthetized. Ultrasound imaging and a pain questionnaire were completed before, during, and after propulsion. The primary outcome was to reposition stones in the collecting system. Secondary outcomes included safety, controllable movement of stones, and movement of stones < 5 mm and ≥ 5 mm. Adverse events were assessed weekly for 3 weeks.
Kidney stones were repositioned in 14 of 15 subjects. Of the 43 targets, 28 (65%) showed some level of movement while 13 (30%) were displaced > 3 mm to a new location. Discomfort during the procedure was rare, mild, brief, and self-limited. Stones were moved in a controlled direction with over 30 fragments being passed by 4 of 6 subjects who previously had a lithotripsy procedure. The largest stone moved was 10 mm. One patient experienced pain relief during treatment of a large stone at the UPJ. In 4 subjects a seemingly large stone was determined to be a cluster of small passable stones once moved.
Ultrasonic propulsion was able to successfully reposition stones and facilitate passage of fragments in humans with no adverse events associated with the investigational procedure.
|
|
|
|
SonoMotion Licenses Technology Commercialization
|
|
|
|
|
|
As a research group, we’re focused on getting to the point of a clinical trial and demonstrating that this works in people. We have to plan going forward to start an ultrasound company that builds a product.
We’ve partnered with the hardware manufacturer who is based in the state of Washington. Our company SonoMotion will add the software to move stones and perform the final testing for that component, and then ship these off all around the world to treat stones. This is a disease that affects five to fifteen percent of the worldwide population.
|
|
Patents Issued
|
 |
|
Noninvasive Fragmentation of Urinary Tract Stones with Focused Ultrasound Patent Number: 12,167,864 |
|
More Info
| |
|
17 Dec 2024
|
|
 |
|
|
A method for attempting to fragment or comminute an object in a body using ultrasound includes producing a burst wave lithotripsy (BWL) waveform by a therapy transducer. The BWL waveform is configured to fragment or comminute the object. The BWL waveform includes a first burst of continuous ultrasound cycles and a second burst of continuous ultrasound cycles. A burst frequency corresponds to a frequency of repeating the bursts of the BWL waveform. The method also includes determining a cycle frequency f of the continuous ultrasound cycles within the first burst and the second burst based on a target fragment size D, where the cycle frequency is: f(MHz)=0.47/D(mm).
|
|
 |
|
Noninvasive Fragmentation of Urinary Tract Stones with Focused Ultrasound Patent Number: 11,583,299 |
|
21 Feb 2023
|
|
 |
 |
|
Ultrasound Based Method and Apparatus for Stone Detection and to Facilitate Clearance Thereof Patent Number: 10,039,562 |
|
More Info
| |
|
7 Aug 2018
|
|
 |
|
|
Described herein are methods and apparatus for detecting stones by ultrasound, in which the ultrasound reflections from a stone are preferentially selected and accentuated relative to the ultrasound reflections from blood or tissue. Also described herein are methods and apparatus for applying pushing ultrasound to in vivo stones or other objects, to facilitate the removal of such in vivo objects.
|
|
 |
|
Ultrasound Based Method and Apparatus for Stone Detection and to Facilitate Clearance Thereof Patent Number: 9,597,103 |
|
More Info
| |
|
21 Mar 2017
|
|
 |
|
|
Described herein are methods and apparatus for detecting stones by ultrasound, in which the ultrasound reflections from a stone are preferentially selected and accentuated relative to the ultrasound reflections from blood or tissue. Also described herein are methods and apparatus for applying pushing ultrasound to in vivo stones or other objects, to facilitate the removal of such in vivo objects.
|
|
 |
|
Ultrasound based method and apparatus for stone detection and to facilitate clearance thereof Patent Number: 9,204,859 |
|
More Info
| |
|
8 Dec 2015
|
|
 |
|
|
Described herein are methods and apparatus for detecting stones by ultrasound, in which the ultrasound reflections from a stone are preferentially selected and accentuated relative to the ultrasound reflections from blood or tissue. Also described herein are methods and apparatus for applying pushing ultrasound to in vivo stones or other objects, to facilitate the removal of such in vivo objects.
|
|
 |
|
Ultrasound Based Method and Apparatus to Determine the Size of Kidney Stone Fragments Before Removal via Ureteroscopy Patent Number: 8,607,634 |
|
More Info
| |
|
17 Dec 2013
|
|
 |
|
|
A transducer is used to send an ultrasound pulse toward a stone and to receive ultrasound reflections from the stone. The recorded time between a pulse that is reflected from the proximal surface and a pulse that is reflected either from the distal surface of the stone or from a surface supporting the stone is used to calculate the stone size. The size of the stone is a function of the time between the two pulses and the speed of sound through the stone (or through the surrounding fluid if the second pulse was reflected by the surface supporting the stone). This technique is equally applicable to measure the size of other in vivo objects, including soft tissue masses, cysts, uterine fibroids, tumors, and polyps.
|
|
 |
|
Method and Apparatus to Detect the Fragmentation of Kidney Stones by Measuring Acoustic Scatter Patent Number: 8,535,250 |
|
More Info
| |
|
17 Sep 2013
|
|
 |
|
|
During shock wave therapy, a determination is made that a kidney stone has begun to fracture, and then a progress of its fragmentation is assessed. This determination can reduce the number of shock waves used to disintegrate kidney stones, and thereby reduce dose-dependent tissue damage. The identification of fracture is possible through the detection and analysis of resonant acoustic scattering, which is the radiation caused by reverberations within a stone particle that is struck by a shock wave. The scattering frequency can provide both an indication that the kidney stone has fragmented, and an indication of the relative sizes of the fragments. Such techniques can be combined with vibro-acoustography based gating that better targets the stone.
|
|
|
|